APP Settles Patent Row Over Generic Blood Thinner
APP Pharmaceuticals LLC and The Medicines Co. signed a deal on Monday that suspends APP's work on producing a generic version of MDCO's blood thinner Angiomax until 2019 and drops all...To view the full article, register now.
Already a subscriber? Click here to view full article